Investor Relations

Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes more »

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings more »

OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources more »

OPKO Lab Receives Accreditation From College of American Pathologists more »

Investor FAQs